Overview

Palbociclib Continuation Study for Participants Continuing From Pfizer-sponsored Palbociclib Clinical Studies

Status:
Not yet recruiting
Trial end date:
2026-04-19
Target enrollment:
Participant gender:
Summary
A continuation study for participants deriving clinical benefit from palbociclib parent studies
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Cetuximab
Fulvestrant
Letrozole
Palbociclib